ClinicalTrials.gg
CompletedNCT04309331Updated Mar 16, 2020

Market Research - Acceptability Trial for a New PKU Amino Acid Based Protein Substitute

An interventional study of Motion in PKU, Phenylketonurias and Inborn Errors of Metabolism, sponsored by Dr. Schär AG / SPA. Completed at 1 site in United Kingdom. Open to participants aged 3 Years to 16 Years. Per ClinicalTrials.gov, last updated 2020-03-16.

Sponsored by Dr. Schär AG / SPA · Not applicable, Interventional, and Other

How we know

From the registry’s dates

  • Registered 1 year 7 months after the study started (first participant enrolled Jul 2018, registered Feb 2020).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
12
Allocation
Not applicable
Ages
3 Years to 16 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 35 studies in Phenylketonurias with a site in United Kingdom — 7 open to participants now, 8 under way, 1 of them phase 3. Phenylketonurias · United Kingdom.

Enrollment
22nd of 27
12 · median 20
Started
2018
with 1 other
No phase
20 of 35
3 open now
Registered
15th of 35
by date
Lead sponsor
2 of 35
Dr. Schär AG / SPA

Among the 35 studies in Phenylketonurias with a site in United Kingdom, this one is the 22nd largest by enrollment of the 27 interventional ones that give a count, is one of 2 that started in 2018, is one of 20 with no phase, and was the 15th registered.

Phenylketonurias

191 studies on the registry are indexed under Phenylketonurias; 40 are open to participants now.

Browse Phenylketonurias studies →

Open to participants now

7 of the 35 studies in Phenylketonurias with a site in United Kingdom are open now. Recruiting first, the newest first:

2 more — sign in →

All 7 open studies →

A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →

Who these studies take

Of the 31 Phenylketonurias studies recruiting now, 14 (45%) set no upper age limit and 17 (55%) stop at 75 or younger; 15 take children under 18; 8 take healthy volunteers.

This study: 3 Years to 16 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 35 studies in Phenylketonurias with a site in United Kingdom, or all of them as a file.
02

Study summary

The aim of this study is to demonstrate that a new protein substitute is acceptable and well tolerated in children with PKU.

03

Conditions studied

  • PKU
  • Phenylketonurias
  • Inborn Errors of Metabolism
  • Metabolic Disease
04

Who can participate

Ages eligible
3 Years to 16 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of PKU or PKU variant requiring a phenylalanine-free protein substitute
  • Subjects who are already taking a phenylalanine-free protein substitute and are willing to try the study product for 7 days
  • Patients aged 3 years of age to adulthood
  • Written obtained from parental caregiver

Exclusion criteria

Exclusion Criteria:

  • Presence of serious concurrent illness
  • Investigator's uncertainty about the willingness or ability of the patient to comply with the protocol requirements
  • Participation in any other studies involving or marketed products concomitantly or within two weeks prior to entry into the study.
  • Any patients having taken antibiotics over the previous 2 weeks leading up to the study.
  • Patients less than 3 years of age.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
12 participants (actual)

Study arms

  • Experimental
    PKU Motion

    amino acid based protein substitute

    Dietary Supplement: Motion

Interventions

  • Dietary supplementMotion

    Amino acid based protein substitute

06

What researchers measure

Primary outcomes

  1. Gastrointestinal tolerance

    Questionnaire detailing any GI symptoms, severity and change from usual • The collection of daily data about the gastro-intestinal tolerance of the protein substitute.

    Time frame: 7 days

  2. Product compliance

    Daily questionnaire on amounts offered and amounts actually consumed, compared to recommended amount.

    Time frame: 7 days

  3. Product palatability

    Questionnaire data captured to evaluate taste

    Time frame: 7 days

  4. Product acceptability

    Brief tick-box questionnaire on overall liking and acceptability of product

    Time frame: 7 days

07

Study locations

1 site
  • Birmingham Children's Hospital
    Birmingham, B4 6NH, United Kingdom
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2018 to primary completion in Sep 2018, 2 months.

Of 33 interventional studies with no phase under Phenylketonurias, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 28. This study's 2 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 13, 2020
First posted
Mar 16, 2020
StartActual
Jul 1, 2018
Primary completionActual
Sep 19, 2018
CompletionActual
Sep 19, 2018
Last update
Mar 16, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 16, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04309331
Lead sponsor
Dr. Schär AG / SPA
Responsible party
Sponsor
First posted
Mar 16, 2020
Start date
Jul 1, 2018
Primary completion
Sep 19, 2018
Completion
Sep 19, 2018
Last update
Mar 16, 2020

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion